Dupilumab biosimilar (Zhuhai Federation Biomedicine)

度普利尤单抗生物类似药（珠海联邦生物医药）

Report date: 2026/04/22 20:01:10

Base Information

Drug NameDupilumab biosimilar (Zhuhai Federation Biomedicine)
Drug Alias NameQL2108QL-2108
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitorsInterleukin-4 inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-13Interleukin-4Interleukin-4 receptor subunit alpha
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai Federation Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Federation Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A